Cogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes. In addition, the company offers Urgent PC System, a neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder; and Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. Further, it provides Macroplastique products for the treatment of vesicoureteral reflux; PTQ Implants to treat fecal incontinence; Urgent PC System for the treatment of fecal incontinence; and VOX Implants to enhance speech and swallowing function in patients with unilateral vocal cord paralysis. Additionally, the company distributes wound care products in the Netherlands and the United Kingdom. Cogentix Medical, Inc. sells its products through a direct sales force and a network of distributor organizations. The company was founded in 1987 and is headquartered in Minnetonka, Minnesota.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGNT
CUSIPN/A
Phone952-426-6140
Debt
Debt-to-Equity RatioN/A
Current Ratio4.66
Quick Ratio3.90
Price-To-Earnings
Trailing P/E Ratio-385.00
Forward P/E Ratio385.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$56.32 million
Price / Sales4.16
Cash Flow$0.0392 per share
Price / Cash98.24
Book Value$1.05 per share
Price / Book3.67
Profitability
EPS (Most Recent Fiscal Year)($0.01)
Net Income$-880,000.00
Net Margins-1.57%
Return on Equity-1.39%
Return on Assets-1.21%
Miscellaneous
Employees208
Outstanding Shares60,910,000
Vision Sciences (NASDAQ:CGNT) Frequently Asked Questions
What is Vision Sciences' stock symbol?
Vision Sciences trades on the NASDAQ under the ticker symbol "CGNT."
How were Vision Sciences' earnings last quarter?
Vision Sciences Inc. (NASDAQ:CGNT) issued its earnings results on Friday, March, 30th. The medical device company reported $0.01 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.01. The medical device company earned $15.54 million during the quarter, compared to analyst estimates of $15.49 million. Vision Sciences had a negative net margin of 1.57% and a negative return on equity of 1.39%. View Vision Sciences' Earnings History.
What price target have analysts set for CGNT?
3 brokers have issued 12-month target prices for Vision Sciences' shares. Their predictions range from $4.00 to $5.00. On average, they anticipate Vision Sciences' stock price to reach $4.5833 in the next year. View Analyst Ratings for Vision Sciences.
Who are some of Vision Sciences' key competitors?
Some companies that are related to Vision Sciences include Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), BioLife Solutions (BLFS), Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES), Viveve Medical (VIVE), Zynex Inc. common stock (ZYXI), Edap Tms (EDAP), Semler Scientific (SMLR), IRIDEX (IRIX), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO) and Stereotaxis (STXS).
Who are Vision Sciences' key executives?
Vision Sciences' management team includes the folowing people:
- Mr. Darin Hammers, Pres, CEO & Director (Age 53)
- Mr. Brett A. Reynolds, Sr. VP, CFO & Corp. Sec. (Age 49)
- Mr. Chris Arnold, VP of Global Sales (Age 50)
- Mr. Larry Heinemann, VP of Corp. Devel. (Age 66)
- Mr. Ash Keswani, Sr. VP of Marketing & Bus. Devel.
Has Vision Sciences been receiving favorable news coverage?
Media stories about CGNT stock have trended positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Vision Sciences earned a coverage optimism score of 0.27 on Accern's scale. They also assigned media stories about the medical device company an impact score of 44.75 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Vision Sciences' major shareholders?
How do I buy shares of Vision Sciences?
Shares of CGNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vision Sciences' stock price today?
One share of CGNT stock can currently be purchased for approximately $3.85.
How big of a company is Vision Sciences?
Vision Sciences has a market capitalization of $234.49 million and generates $56.32 million in revenue each year. The medical device company earns $-880,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Vision Sciences employs 208 workers across the globe.
How can I contact Vision Sciences?
Vision Sciences' mailing address is 5420 FELTL ROAD, MINNETONKA MN, 55343. The medical device company can be reached via phone at 952-426-6140 or via email at [email protected]
MarketBeat Community Rating for Vision Sciences (CGNT)
MarketBeat's community ratings are surveys of what our community members think about Vision Sciences and other stocks. Vote "Outperform" if you believe CGNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
